Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Catalyst Pharmaceuticals, Inc. - Common Stock
(NQ:
CPRX
)
20.25
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 11, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Catalyst Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
How Is The Market Feeling About Catalyst Pharmaceuticals?
September 09, 2025
Via
Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top GARP Investment with Strong Growth and Reasonable Valuation
September 09, 2025
Catalyst Pharmaceuticals (CPRX) is a top GARP stock with strong growth, excellent profitability, and an attractive valuation, making it a compelling long-term investment.
Via
Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a High-Quality Caviar Cruise Candidate
September 03, 2025
Catalyst Pharmaceuticals (CPRX) excels in growth, profitability, and financial health, making it a top-quality stock for long-term investors according to the Caviar Cruise screen.
Via
Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Value Investment in Biotech
August 22, 2025
Catalyst Pharmaceuticals (CPRX) is a strong value stock with low P/E ratios, high profitability, zero debt, and impressive growth, offering a solid margin of safety.
Via
Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Top Affordable Growth Stock with Strong Fundamentals
August 19, 2025
Catalyst Pharmaceuticals (CPRX) offers strong growth, fair valuation, and solid financials, making it a top pick for investors seeking affordable growth in biotech.
Via
Chartmill
Earnings Scheduled For August 6, 2025
August 06, 2025
Via
Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Fits Louis Navellier’s Growth Investing Strategy with Strong Earnings Momentum and Rising Sales
August 06, 2025
Louis Navellier’s growth investing strategy highlights stocks like Catalyst Pharmaceuticals (CPRX), which shows strong earnings momentum, rising sales, and high profitability. CPRX meets key criteria,...
Via
Chartmill
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Growth Stock with Breakout Potential
August 02, 2025
Combine technical & fundamental analysis to spot growth stocks like Catalyst Pharmaceuticals (CPRX), showcasing strong financials & breakout potential.
Via
Chartmill
Is the Market Bullish or Bearish on Catalyst Pharmaceuticals?
July 31, 2025
Via
Benzinga
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) – A Value Stock with Strong Fundamentals and Growth Potential
July 29, 2025
Catalyst Pharmaceuticals (CPRX) is a value stock with strong fundamentals—low P/E, zero debt, high profitability, and robust growth, making it a standout in biotech.
Via
Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Strong Contender in Affordable Growth Stocks
July 21, 2025
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it a standout in affordable growth stocks.
Via
Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Strong Contender for Growth Investors
July 16, 2025
Catalyst Pharmaceuticals (CPRX) meets Louis Navellier's growth criteria with strong earnings, sales growth, and high profitability, making it an attractive stock for growth investors.
Via
Chartmill
Peering Into Catalyst Pharmaceuticals's Recent Short Interest
July 14, 2025
Via
Benzinga
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Growth Stock with Technical Breakout Potential
July 12, 2025
CATALYST PHARMACEUTICALS (CPRX) shows strong growth, profitability, and a promising technical setup, making it a stock to watch.
Via
Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Rare Biotech With Undervalued Potential
July 07, 2025
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, profitability, and financial health at an undervalued price, making it a rare biotech stock for value investors.
Via
Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender in Affordable Growth Stocks
June 30, 2025
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth stocks.
Via
Chartmill
Is Catalyst Pharmaceuticals Gaining or Losing Market Support?
June 27, 2025
Via
Benzinga
Top 3 Health Care Stocks You'll Regret Missing This Quarter
June 26, 2025
Via
Benzinga
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A CANSLIM Candidate With Strong Growth Metrics
June 26, 2025
CATALYST PHARMACEUTICALS (CPRX) meets key CANSLIM criteria with strong earnings growth, high profitability, and market-leading relative strength. A debt-free balance sheet adds appeal.
Via
Chartmill
CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug
June 23, 2025
CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug.
Via
Investor's Business Daily
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for Growth Investors
June 23, 2025
CATALYST PHARMACEUTICALS INC (CPRX) shows strong earnings growth, high profitability, and solid cash flow, making it a standout for growth investors.
Via
Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Rare Combination of Growth and Value
June 07, 2025
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and an attractive valuation, making it a standout in biotech.
Via
Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for CANSLIM Investors
June 04, 2025
CATALYST PHARMACEUTICALS (CPRX) meets CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A technical uptrend and reasonable valuation add to its appeal.
Via
Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for Growth Investors
June 02, 2025
CATALYST PHARMACEUTICALS INC (CPRX) meets key growth criteria from Louis Navellier’s strategy, with strong earnings, revenue growth, and solid financial health. A detailed analysis highlights its...
Via
Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for Quality Investors
May 24, 2025
Catalyst Pharmaceuticals (CPRX) shows strong fundamentals, high profitability, and zero debt, making it a compelling choice for quality investors. The stock trades at reasonable valuations with solid...
Via
Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Growth Stock with Technical Breakout Potential
May 21, 2025
CATALYST PHARMACEUTICALS (CPRX) shows strong growth, profitability, and a bullish technical setup, making it a stock to watch in the biotech sector.
Via
Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A High Growth Momentum Stock with Strong Technical Setup
May 19, 2025
CATALYST PHARMACEUTICALS (CPRX) shows strong earnings momentum and a bullish technical setup, making it a candidate for high-growth investors.
Via
Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - A Strong Candidate for Affordable Growth Investors
May 15, 2025
CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive option for investors seeking affordable growth stocks in biotech.
Via
Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is a candidate for high growth investors. Here's why.
May 15, 2025
A fundamental and technical analysis of (NASDAQ:CPRX): Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is Poised for High Growth.
Via
Chartmill
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for CANSLIM Investors
May 13, 2025
CATALYST PHARMACEUTICALS (CPRX) meets CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A top pick for growth investors.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.